Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden

David Bomze; Omar Hasan Ali; Andrew Bate; Lukas Flatz

doi:10.1001/jamaoncol.2019.3221

Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden

JAMA Oncol. 2019 Nov 1;5(11):1633-1635. doi: 10.1001/jamaoncol.2019.3221.

Authors

David Bomze¹, Omar Hasan Ali², Andrew Bate³, Lukas Flatz¹

Affiliations

¹ Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland.
² Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
³ Division of Translational Medicine, Department of Medicine, NYU School of Medicine, New York, New York.

Abstract

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.